- World Pharma News Home » Clinical Trials » Anavex completes successful preclinical studies on lead Alzheimer's drug candidate
(a free service delivered by FeedBurner)
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. This success enables ANAVEX to start preparing the Investigational New Drug (IND) (or IMPD) file to move to Phase 1 human clinical trials.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments